Late-onset symptomatic hyperprolactinemia in 6-pyruvoyl-tetrahydropterin synthase deficiency

Orphanet J Rare Dis. 2023 Nov 10;18(1):351. doi: 10.1186/s13023-023-02963-4.

Abstract

Background: Tetrahydrobiopterin (BH4) deficiency caused by 6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency is a rare disorder that is one of the major causes of hyperphenylalaninemia in Taiwan.

Methods: In this study, we reviewed the clinical courses of 12 adolescent and adult patients (7 females and 5 males) with PTPS deficiency.

Results: The patients were treated shortly after diagnosis through newborn screening with a combination of BH4, levodopa/carbidopa, and 5-OH-tryptophan. Their plasma phenylalanine and tyrosine levels were well controlled, and their prolactin levels were also decreased after treatment. However, their prolactin levels gradually rose as they grew into puberty, and at a current age of 27.5 [interquartile range (IQR 7.9)] years, five of the 12 patients had either highly elevated prolactin levels (> 100 ng/mL in one male patient, normal reference values, male < 11 ng/mL, female < 17 ng/mL) or symptoms, including irregular menstruation, amenorrhea, and breast swelling (in four female patients). The dosage of levodopa in these five patients (14.3 (IQR 3.0) mg/kg/day) was slightly higher than that in the other patients (p = 0.05). Magnetic resonance imaging studies did not reveal an increase in the size of the anterior pituitary gland, although a Rathke cleft cyst was found in one patient. Two patients received cabergoline treatment, which promptly lowered prolactin levels and relieved symptoms.

Conclusions: Hyperprolactinemia is common in female patients with PTPS deficiency, especially after puberty. A long-acting dopamine agonist, such as cabergoline, may be a necessary adjunctive treatment for most patients with BH4 deficiency.

Keywords: 6-Pyruvoyl-tetrahydropterin synthase deficiency; BH4; Hyperphenylalaninemia; Hyperprolactinemia; PTPS; Tetrahydrobiopterin deficiency.

Publication types

  • Review
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Cabergoline / therapeutic use
  • Female
  • Humans
  • Hyperprolactinemia* / drug therapy
  • Infant, Newborn
  • Levodopa / therapeutic use
  • Male
  • Phenylketonurias*
  • Prolactin / metabolism

Substances

  • Cabergoline
  • Levodopa
  • Prolactin

Supplementary concepts

  • 6-pyruvoyl-tetrahydropterin synthase deficiency